Charles River Laboratories
564 hedge funds and large institutions have $8.03B invested in Charles River Laboratories in 2025 Q1 according to their latest regulatory filings, with 67 funds opening new positions, 189 increasing their positions, 244 reducing their positions, and 135 closing their positions.
1% more capital inflows, than outflows
Capital inflows: $1.38B | Capital outflows: $1.36B
0.84% more ownership
Funds ownership: 103.63% → 104.46% (+0.84%)
12% less funds holding
Funds holding: 641 → 564 (-77)
16% less call options, than puts
Call options by funds: $106M | Put options by funds: $125M
23% less repeat investments, than reductions
Existing positions increased: 189 | Existing positions reduced: 244
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
50% less first-time investments, than exits
New positions opened: 67 | Existing positions closed: 135
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$345M |
| 2 |
Goldman Sachs
New York
|
+$134M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$90.3M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$79.2M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$59.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Meritage Group
San Francisco,
California
|
-$198M |
| 2 |
Southpoint Capital Advisors
New York
|
-$111M |
| 3 |
BlackRock
New York
|
-$94.1M |
| 4 |
M.D. Sass LLC
New York
|
-$72.3M |
| 5 |
Millennium Management
New York
|
-$49.9M |
CRL Hedge Fund Activity: Q1 2025 in Review
564 of the 7,486 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q1 2025, worth a combined $8.03B — down 18% from $9.8B a quarter earlier.
Sellers outnumbered buyers: 135 funds closed out of CRL and 67 opened new positions — a net loss of 68 holders — while 244 trimmed existing stakes and 189 added.
The largest buyer was UBS Group, adding an estimated $345M. The largest seller was Meritage Group, exiting entirely with an estimated $198M sold.
- 564 institutional investors held Charles River Laboratories (CRL) as of Q1 2025, down from 641 in Q4 2024.
- Funds reported $8.03B of Charles River Laboratories stock for Q1 2025, down 18% quarter-over-quarter.
- 67 funds opened new Charles River Laboratories positions in Q1 2025 and 135 closed out, a net change of -68 holders.
- The largest Charles River Laboratories buyer in Q1 2025 was UBS Group, an estimated $345M added.
- The largest Charles River Laboratories seller in Q1 2025 was Meritage Group, an estimated $198M sold.
Based on aggregated 13F filings for Q1 2025.